DGAP-News: Interim Report for the 6 months ended June 30, 2011
ID: 455746
03.08.2011 17:31
---------------------------------------------------------------------------
- Continued strong focus on cost control with improvement in first half
operating loss and cash burn over 2010
- Improving 2011 guidance as result of DKK 25 million reduction in operating
expenses
- Announced HuMax-CD74(TM) antibody-drug conjugate program with Seattle Genetics
- Decisive move to minimize future spending by winding down the zalutumumab
program
In order to read Genmab's Interim Report for the 6 months ended June 30, 2011
please see the attached file.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations&Communication
T: +45 33 44 77 20
M: +45 25 12 62 60
E: r.gravesen@genmab.com
www.genmab.com
Company Announcement no. 24
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
03.08.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Datum: 03.08.2011 - 17:31 Uhr
Sprache: Deutsch
News-ID 455746
Anzahl Zeichen: 1951
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 353 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Interim Report for the 6 months ended June 30, 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
Genmab A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
